28-Jul-2025
No headlines found.
Prothena to Report Second Quarter 2025 Financial Results on August 4
Business Wire (Mon, 28-Jul 4:05 PM ET)
Prothena Announces Corporate Restructuring
Business Wire (Wed, 18-Jun 4:05 PM ET)
Business Wire (Mon, 16-Jun 1:06 AM ET)
Business Wire (Fri, 23-May 4:05 PM ET)
Prothena Reports First Quarter 2025 Financial Results and Business Highlights
Business Wire (Thu, 8-May 4:05 PM ET)
Prothena to Report First Quarter 2025 Financial Results on May 8
Business Wire (Thu, 1-May 4:05 PM ET)
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Prothena PLC - trades on the NASDAQ stock market under the symbol PRTA.
As of July 28, 2025, PRTA stock price climbed to $6.87 with 742,327 million shares trading.
PRTA has a beta of 1.24, meaning it tends to be more sensitive to market movements. PRTA has a correlation of 0.10 to the broad based SPY ETF.
PRTA has a market cap of $369.79 million. This is considered a Small Cap stock.
Last quarter Prothena PLC - reported $3 million in Revenue and -$1.12 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.09.
In the last 3 years, PRTA traded as high as $79.65 and as low as $4.32.
The top ETF exchange traded funds that PRTA belongs to (by Net Assets): IWM, VXF, IWN, IBB, VTWO.
PRTA has underperformed the market in the last year with a return of -71.9%, while the SPY ETF gained +18.3%. In the last 3 month period, PRTA fell short of the market, returning -28.8%, while SPY returned +15.9%. However, in the most recent 2 weeks PRTA has outperformed the stock market by returning +6.8%, while SPY returned +1.9%.
PRTA support price is $6.48 and resistance is $6.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRTA shares will trade within this expected range on the day.